心房颤动药物治疗的新靶点

Novel Targets of Pharmacological Therapies at Atrial Fibrillation

心房颤动是临床上常见的,具有高发病率及病死率的一种快速性心律失常,而目前还没有安全有效的心房颤动治疗方法能完全解决这一医学难题。新近提出的心房选择性药物策略可能是心房颤动治疗新的选择。这些心房选择性药物靶点涉及多种离子通道,包括钠通道、钾通道、阳离子通道等等。这些药物作用于心房肌发挥抗心律失常作用,但极少影响心室肌,从而避免产生室性心律失常作用。现就目前已较多研究的几个心房颤动相关离子通道治疗靶点入手,详细介绍在使用或研发的药物。

Atrial fibrillation （AF） is the most common tachycardia and is associated with increased morbidily and mortality. Develop- ment of safe and effective treatments for AF is one of the greatest medical needs facing our society. The current atrial-selective pharmacologic strategy represents promising novel therapeutic options for the treatment of AF. The atrial-selective targets of anti-AF are involved in multiple ion channels, which include sodium channels, potassium channels and cation channels. These novel drugs possess anti-arrhythmic activity by effecting on atrium, but produce little to no efi^ct on ventricular electrophysiologic parameters, which avoid the genesis of ventricular ar- rhythmia. This review focuses on several targets of anti-AF related with ion channels and new drugs on clinical practice or ongoing development.